Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Stevens-Johnson syndrome (SJS), also called erythema multiforme ... In addition, hepatitis, nephritis, gastrointestinal bleeding, pneumonia, arthritis, arthralgia, fever, and myalgia have all ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Metabolic syndrome is a constellation of conditions that together increase the risk of type 2 diabetes, stroke, and cardiovascular problems, including heart attack. The features of metabolic syndrome ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated 'FAIR' by InvestingPro's Financial Health scoring system, has announced updates on the enrollment of its clinical ...

Despite affecting over 30 million Americans, COPD remains dangerously underdiagnosed. As a leading cause of death, this chronic respiratory disease continues to claim lives, yet awareness and early ...

Only two patients in this series had nephritis; the urinary sediment of one of these patients normalized, but the second did not complete the course because of the retinal artery thrombosis.